<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02332356</url>
  </required_header>
  <id_info>
    <org_study_id>MREC study</org_study_id>
    <nct_id>NCT02332356</nct_id>
  </id_info>
  <brief_title>Therapeutic Optimization Study Based on MR Enterocolonography in Patients With Crohn's Disease</brief_title>
  <official_title>Therapeutic Optimization Study Based on MR Enterocolonography in Patients With Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tokyo Medical and Dental University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tokyo Medical and Dental University</source>
  <brief_summary>
    <textblock>
      This randomized, controlled study aims to evaluate the impact of therapeutic intervention
      (step up) for the patients who are clinical remission with Magnetic Resonance
      Enterocolonography (MREC) active. In addition, to evaluate the impact of therapeutic step
      down for the patients who archived clinical and MREC remission. The primary endpoint is the
      rate of clinical remission at 104 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2014</start_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of clinical remission at 104 weeks.</measure>
    <time_frame>104 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The rate of hospitalization and operation</measure>
    <time_frame>104 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Crohn Disease</condition>
  <arm_group>
    <arm_group_label>step up</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Procedure: MREC patients receive therapeutic step up</description>
  </arm_group>
  <arm_group>
    <arm_group_label>observation step up</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>step down</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Procedure: MREC patients receive therapeutic step down</description>
  </arm_group>
  <arm_group>
    <arm_group_label>observation step down</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>azathioprine or adalimumab and infliximab</intervention_name>
    <arm_group_label>step up</arm_group_label>
    <arm_group_label>step down</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of Crohn's and proven history of disease with clinical remission
             (CDAI&lt;150)

          -  Signed written consent form to enroll the study (Need agreement from deputy for
             patients under 20years old)

        Exclusion Criteria:

          -  Contraindication for infliximab, adalimumab, or azathioprine

          -  Lactating woman

          -  Presence of malignancy

          -  Within 3 month from intestinal surgery

          -  Presence of an end stoma

          -  Planned surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Toshimitsu Fujii</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tokyo Medical and Dental University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toshimitsu Fujii</last_name>
    <phone>+81 3 58035877</phone>
    <email>tfujii.gast@tmd.ac.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gastroenterology and Hepatology, Tokyo Medical and Dental UNIV</name>
      <address>
        <city>Tokyo</city>
        <zip>113-8519</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Toshimitsu Fujii</last_name>
      <phone>+81 3 58035877</phone>
      <email>tfujii.gast@tmd.ac.jp</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <reference>
    <citation>Takenaka K, Ohtsuka K, Kitazume Y, Nagahori M, Fujii T, Saito E, Naganuma M, Araki A, Watanabe M. Comparison of magnetic resonance and balloon enteroscopic examination of the small intestine in patients with Crohn's disease. Gastroenterology. 2014 Aug;147(2):334-342.e3. doi: 10.1053/j.gastro.2014.04.008. Epub 2014 Apr 13.</citation>
    <PMID>24732015</PMID>
  </reference>
  <reference>
    <citation>Hyun SB, Kitazume Y, Nagahori M, Toriihara A, Fujii T, Tsuchiya K, Suzuki S, Okada E, Araki A, Naganuma M, Watanabe M. Magnetic resonance enterocolonography is useful for simultaneous evaluation of small and large intestinal lesions in Crohn's disease. Inflamm Bowel Dis. 2011 May;17(5):1063-72. doi: 10.1002/ibd.21510. Epub 2010 Oct 25.</citation>
    <PMID>21484957</PMID>
  </reference>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2015</study_first_submitted>
  <study_first_submitted_qc>January 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2015</study_first_posted>
  <last_update_submitted>January 4, 2015</last_update_submitted>
  <last_update_submitted_qc>January 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tokyo Medical and Dental University</investigator_affiliation>
    <investigator_full_name>Toshimitsu Fujii, MD PhD</investigator_full_name>
    <investigator_title>Gastroenterology and Hepatology</investigator_title>
  </responsible_party>
  <keyword>Crohn Disease</keyword>
  <keyword>Inflammatory Bowel Diseases</keyword>
  <keyword>Disease Attributes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
    <mesh_term>Infliximab</mesh_term>
    <mesh_term>Azathioprine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

